Journal ArticleDOI
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Reads0
Chats0
TLDR
The current diagnostic approach, their pathology, natural course, and common complications, the assessment of disease activity, extraintestinal manifestations, and medical and surgical management are discussed, and diagnostic and therapeutic algorithms are provided.About:
This article is published in The Lancet.The article was published on 2007-05-12. It has received 1677 citations till now. The article focuses on the topics: Inflammatory bowel disease & Alicaforsen.read more
Citations
More filters
Journal ArticleDOI
Inflammatory bowel disease: cause and immunobiology
TL;DR: How environmental factors, infectious microbes, ethnic origin, genetic susceptibility, and a dysregulated immune system can result in mucosal inflammation are discussed.
Journal ArticleDOI
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders.
Fernando Magro,Paolo Gionchetti,Rami Eliakim,Sandro Ardizzone,Alessandro Armuzzi,Manuel Barreiro-de Acosta,Johan Burisch,Krisztina Gecse,Ailsa Hart,Pieter Hindryckx,Cord Langner,Jimmy K. Limdi,Gianluca Pellino,Edyta Zagórowicz,Tim Raine,Marcus Harbord,Florian Rieder +16 more
TL;DR: This research presents a meta-analyses of Gastroenterology and Hepatology at the cellular and molecular level, which shows clear trends in the development of immune-oncology-metabolical pathways towards “clinically checkpoints”.
Journal ArticleDOI
Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
Jean-Frederic Colombel,Paul Rutgeerts,Walter Reinisch,Dirk Esser,Yanxin Wang,Yinghua Lang,Colleen Marano,Richard Strauss,Björn J. Oddens,Brian G. Feagan,Stephen B. Hanauer,Gary R. Lichtenstein,Daniel H. Present,Bruce E. Sands,William J. Sandborn +14 more
TL;DR: The degree of mucosal healing after 8 weeks of infliximab was correlated with improved clinical outcomes including colectomy, and similar trends were observed for all outcomes except coLECTomy among the subgroup with clinical response at week 8.
Journal ArticleDOI
Second European Evidence-Based Consensus on the Diagnosis and Management of Ulcerative Colitis Part 1: Definitions and Diagnosis
Axel Dignass,Rami Eliakim,Fernando Magro,Christian Maaser,Yehuda Chowers,Karel Geboes,Gerassimos J. Mantzaris,Walter Reinisch,Jean-Frederic Colombel,Severine Vermeire,Simon Travis,James O. Lindsay,Gert Van Assche +12 more
TL;DR: The aim of the Consensus is to promote a European perspective on the management of ulcerative colitis and its dilemmas to avoid duplication of effort in the future.
Journal ArticleDOI
Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial.
Damián García-Olmo,Dolores Herreros,Isabel Pascual,José Antonio Pascual,Emilio Del-Valle,Jaime Zorrilla,Paloma De-La-Quintana,Mariano García-Arranz,Maria Pascual +8 more
TL;DR: Administration of expanded ASCs (20 to 60 million cells) in combination with fibrin glue is an effective and safe treatment for complex perianal fistula and appears to achieve higher rates of healing than fibr in glue alone.
References
More filters
Journal ArticleDOI
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B. Hanauer,Brian G. Feagan,Gary R. Lichtenstein,Lloyd Mayer,Stefan Schreiber,Jean-Frederic Colombel,Daniel Rachmilewitz,Douglas C. Wolf,Allan Olson,Weihang Bao,Paul Rutgeerts +10 more
TL;DR: Patients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remission at weeks 30 and 54, to discontinue corticosteroids, and to maintain their response for a longer period of time, if inflIXimab treatment is maintained every 8 weeks.
Journal ArticleDOI
Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts,William J. Sandborn,Brian G. Feagan,Walter Reinisch,Allan Olson,Jewel Johanns,Suzanne Travers,Daniel Rachmilewitz,Stephen B. Hanauer,Gary R. Lichtenstein,Willem J.S. de Villiers,Daniel H. Present,Bruce E. Sands,Jean-Frederic Colombel +13 more
TL;DR: Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Journal ArticleDOI
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
Stephan R. Targan,Stephen B. Hanauer,S. J. H. Van Deventer,Lloyd Mayer,Daniel H. Present,T. Braakman,K. L. Dewoody,T. F. Schaible,Paul Rutgeerts +8 more
TL;DR: A 12-week multicenter, double-blind, placebo-controlled trial of cA2 in 108 patients with moderate-to-severe Crohn's disease that was resistant to treatment, finding clinical response, the primary end point, was a reduction of 70 or more points in the score on theCrohn's Disease Activity Index at four weeks.
Journal ArticleDOI
Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg,Jack Satsangi,Tariq Ahmad,Ian D. Arnott,Charles N. Bernstein,Steven R. Brant,Renzo Caprilli,Jean-Frederic Colombel,Christoph Gasche,Karel Geboes,Derek P. Jewell,Amir Karban,Edward V. Loftus,A. Salvador Peña,Robert H. Riddell,David B. Sachar,Stefan Schreiber,A. Hillary Steinhart,Stephan R. Targan,Severine Vermeire,Bryan F. Warren +20 more
TL;DR: The introduction of a widely acceptable clinical subclassification is strongly advocated, which would allow detailed correlations among serotype, genotype and clinical phenotype to be examined and confirmed in independent cohorts of patients and, thereby, provide a vital foundation for future work.
Journal ArticleDOI
Infliximab for the treatment of fistulas in patients with Crohn's disease.
Daniel H. Present,Paul Rutgeerts,Stephan R. Targan,Stephen B. Hanauer,Lloyd Mayer,R. A. van Hogezand,Daniel K. Podolsky,Bruce E. Sands,T. Braakman,K. L. Dewoody,Th.F. Schaible,S. J. H. Van Deventer +11 more
TL;DR: Infliximab is an efficacious treatment for fistulas in patients with Crohn's disease and the most common adverse events for patients treated with infliximab were headache, abscess, upper respiratory tract infection, and fatigue.